Viridian Therapeutics Inc (VRDN)
Viridian Therapeutics, Inc. is a clinical-stage biotechnology company listed on the NASDAQ under the ticker VRDN. The company focuses on discovering, developing, and commercializing treatments for serious and rare diseases. Its pipeline includes IGF-1R therapies for thyroid eye disease, such as Veligrotrug, a humanized monoclonal antibody administered intravenously, and Elegrobart, a subcutaneous IGF-1R candidate designed for lower-volume, less frequent dosing. Viridian is also advancing an anti-thyroid-stimulating hormone receptor candidate for Graves' disease and thyroid eye disease, along with engineered neonatal Fc receptor inhibitors including VRDN-006 and VRDN-008. The company was incorporated in 2010 and is headquartered in Waltham, Massachusetts. It previously operated as Miragen Therapeutics, Inc. before adopting its current name in January 2021.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-VRDN
|
$19.95
|
6.5% Upside
|
Fair
|
$36.13
|
92.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-6.8x
|
4.1x
|
29.1x
|
2.05 B
|
1.488 B
|
2.4%
|
94.8%
|
5.1
|
—
|
100.2%
|
